Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
What is the ticker symbol for Galera Therapeutics Inc? What does GRTX stand for in stocks?
GRTX is the stock ticker symbol of Galera Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Galera Therapeutics Inc (GRTX)?
As of Wed Nov 20 2024, market cap of Galera Therapeutics Inc is 2.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of GRTX stock?
You can check GRTX's fair value in chart for subscribers.
Is Galera Therapeutics Inc a good stock to buy?
The fair value guage provides a quick view whether GRTX is over valued or under valued. Whether Galera Therapeutics Inc is cheap or expensive depends on the assumptions which impact Galera Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRTX.